Postmenopausal Osteoporosis Market 2020-2026
|出版商||Orion Market Research Pvt Ltd||商品編碼||1008113|
|停經後骨質疏鬆症市場:2020∼2026年 Postmenopausal Osteoporosis Market 2020-2026|
|出版日期: 2021年05月04日||內容資訊: 英文||
在預測期內，全球絕經後骨質疏鬆症市場預計將以約 3.6% 的複合年增長率增長。促進市場增長的因素包括骨質疏鬆症患病率的增加和新興經濟體醫療基礎設施的改善。人們依賴吸煙和飲酒的生活方式改變、對該疾病認識的提高、藥物進化和 FDA 批准也推動了市場增長。此外，產品審批和監管過程中的高標準、與仿製藥的競爭、專利到期都會阻礙市場增長。新應用的開發、產品設計的創新以及各個市場參與者的地域擴張為市場增長創造了機會。。
Global Postmenopausal Osteoporosis Market Size, Share & Trends Analysis Report by Treatment (Bisphosphonates, Hormones, Strontium Ranelate, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce Pharmacies) Forecast 2021-2027
The global postmenopausal osteoporosis market is anticipated to grow at a CAGR of around 3.6% during the forecast period. Osteoporosis is a form of disorder caused by skeletal fragility, low bone mass, and microarchitectural. It results in a condition where bone mass and bone density decrease that may increase the chances of bone fracture in long run. The factors contributing to the growth of the market include the growing prevalence of osteoporosis and improvement in healthcare infrastructure in emerging economies. Additionally, changing lifestyles where people are addicted to smoking and alcohol and increasing awareness among people regarding the disorder and advancement in drugs and approval by the FDA is also driving the growth of the market. Moreover, the higher standards approval regulation process of products, rising generic competition, and patent expiration will be hampering the growth of the market. Moreover, new application developments and innovation in product designs and geographic expansions by various market players are creating an opportunity for market growth.
The global postmenopausal osteoporosis market is segmented based on the treatment and distribution channel. Based on treatment, the market is segmented into bisphosphonates, hormones, strontium ranelate, and others. Further on the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, e-commerce pharmacies.
Global Postmenopausal Osteoporosis Market Share by Treatment, 2020 (%)
Source: OMR Global
The bisphosphonates segment is projected to have a significant share in the global Postmenopausal Osteoporosis Market
Among treatment, the bisphosphonates segment projected to have a considerable share in the market. These are a group of drugs that treats slowing bone loss. It also reduces the risk of hip and spine fractures in osteoporosis. These are used at different doses that support in treating Paget's disease of bone. Bisphosphonates are usually well tolerated by patients and the risk of digestive problems with oral preparations is reduced while taken carefully following the instructions. It has very few side effects including, a sore mouth, muscle pain, headaches, flu, bone pain, and others. People with severe kidney problems, pregnant women, people who are taking parathyroid hormone currently, and people with esophagitis cannot take bisphosphonates. Different types of bisphosphonates include ibandronic acid, zoledronic acid, sodium clodronate, and disodium pamidronate. The various advantages of bisphosphonates include it prevents bone loss, improves bone strength and preserves the bone structure, and reduces the fracture risks in patients with osteoporosis.
The global postmenopausal osteoporosis market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America is projected to dominate the market during the forecast period of 2021 followed by Europe attributed to factors such as early adoption rates of treatments, growing aged population who more have chances of the osteoporosis disease. Whereas Europe has been considered as the second largest region attributing to factors such as high diagnostic rates and better healthcare infrastructure in the region.
Global Postmenopausal Osteoporosis Market Growth, by Region 2021-2027
Source: OMR Global
Asia-Pacific will have considerable growth in the global postmenopausal osteoporosis market
Asia-Pacific is projected to grow at a significant CAGR in the postmenopausal osteoporosis market during the forecast period. The growth is attributed to increasing healthcare spending and improvement in healthcare infrastructure in the region. The simultaneous development in the medical tourism industry in the following industry also propelling the market growth. Major players including Eily Lily and Co, Pfizer Inc, Protector& Gamble are also having their operation in the region and contributing significantly to the growth of the market.
Market Players Outlook
The key players of the postmenopausal osteoporosis market include Eli Lilly and CO., Pfizer Inc., Proctor & Gamble Co., Amgen Inc., Novartis International AG, Allergan plc, and others. The market players are considerably contributing to the market growth by adopting various strategies including mergers, and acquisitions, collaborations, and new product launches. For instance, in December 2018, GlaxoSmithKline plc and TESARO Inc announced that GSK will be acquiring TESARO that is an oncology-focused company. This acquisition will be strengthening GSK pharmaceutical business along with accelerating the GSK pipeline and its commercial capability in the oncology business.
The Report Covers
Market value data analysis of 2020 and forecast to 2027.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global Postmenopausal Osteoporosis market.
Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where in the market.